LIGHT-CORM-CAT

Development of novel Near-infrared Light-triggered CORMs for Cancer Treatment

 Coordinatore HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV 

 Organization address address: BAUTZNER LANDSTRASSE 400
city: DRESDEN
postcode: 1328

contact info
Titolo: Dr.
Nome: Rainer
Cognome: Maletti
Email: send email
Telefono: +49 351 2603462
Fax: +49 351 2602700

 Nazionalità Coordinatore Germany [DE]
 Totale costo 274˙336 €
 EC contributo 274˙336 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-IOF
 Funding Scheme MC-IOF
 Anno di inizio 2015
 Periodo (anno-mese-giorno) 2015-04-13   -   2018-04-12

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV

 Organization address address: BAUTZNER LANDSTRASSE 400
city: DRESDEN
postcode: 1328

contact info
Titolo: Dr.
Nome: Rainer
Cognome: Maletti
Email: send email
Telefono: +49 351 2603462
Fax: +49 351 2602700

DE (DRESDEN) coordinator 274˙336.80

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

release    clinical    treatment    corms    visible    cells    living    techniques    light    carbon    trials    molecules    therapeutic    co    monoxide    interaction    cancer    activated   

 Obiettivo del progetto (Objective)

'The capacity for imaging and treatment with a single assembly (“theranostic”) is a promising advance that seeks to further improve personalised cancer treatment. This project aims to contribute a revolutionary step to this field through the development of near-infrared light-activated carbon monoxide-releasing molecules (NIRA-CORMs). Carbon monoxide plays an important role in the regulation of stress response and in cell adaption to injury. Moreover, pre-clinical trials applying this gas as a therapeutic agent have already shown that it has therapeutic effects. As a consequence, the development of molecules that can release CO in a highly controlled fashion (CORMs) under physiological conditions has therefore become a major field of scientific and medical interest. So far, very little is actually known about the interaction of CORMs with living cells, both before and after release of CO. This represents a major barrier to their progression into clinical trials. To overcome these obstacles, a combination of new methodology and novel CORMs will not only provide a new non-invasive technology to elucidate the interaction of CO and CORMs with living organisms, but also deliver agents that can be used to simultaneously monitor and treat diseases in a specific and safe manner with optical-based techniques. This approach consists of upconverting nanoparticles (UCNPs), which harvest NIR light and emit visible light, decorated with ruthenium-based, visible light-activated CORMs and a tumour-targeting peptide. It will be the first study of its kind to probe in detail the uptake, trafficking and light-triggered activation of photo-CORMs in cells using a suite of high-resolution spectroscopic techniques in the multidisciplinary environment at Monash University and Helmholtz-Zentrum Dresden-Rossendorf. The applicant has the opportunity to learn a lot of new research methods in the field of cancer theranostics, and it is a crucial step in developing her independent carrier.'

Altri progetti dello stesso programma (FP7-PEOPLE)

ZF OPTOGENETICS (2010)

Optogenetic analysis of neural circuits controlling behavior in zebrafish

Read More  

EUROCLAST (2013)

Exploring Functional and Developmental Osteoclast Heterogeneity in Health and Disease

Read More  

ELWBINSTEM (2014)

Development of electrochemical water based in-situ TEM and study of platinum based nanoparticles potential- and time-dependent changes

Read More